T

    TriSalus Life Sciences Inc. (TLSI)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $4.95
    +0.12 (+2.48%)

    Market Cap: $297.40M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    36%(4/11)
    Avg Surprise
    -38.23%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.15 - $-0.09
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.10+18.0%
    60d ago$-0.10+18.0%
    30d ago$-0.10+18.0%
    7d ago$-0.13+0.0%
    Current$-0.13
    Revenue Consensus
    $14M
    Range$13M - $15M
    4 analysts
    Dec 31, 2026
    EPS Consensus$0.11
    Range$0.05 - $0.17
    4 analysts
    Revenue Consensus
    $18M
    Range$14M - $19M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.11---
    Sep 26EST
    		-$-0.13---
    Jun 26
    		$-0.16$-0.15-6.67%Miss+30.4%
    Mar 26
    		$0.03N/A+118.38%Beat+108.9%
    Dec 25
    		$-0.05N/A+61.54%Beat+87.5%
    Sep 25
    		$-0.87$-0.16-443.75%Miss-117.5%
    Jun 25
    		$-0.23$-0.22-4.55%Miss-9.5%
    Mar 25
    		$-0.33$-0.20-65.00%Miss+45.0%
    Dec 24
    		$-0.40$-0.35-14.29%Miss+74.4%
    Sep 24
    		$-0.40$-0.36-11.11%Miss-202.1%
    Jun 24
    		$-0.21N/A+54.35%Beat-70.3%
    Mar 24
    		$-0.60$-0.72+16.67%Beat-998.9%
    Dec 23
    		$-1.56$-0.69-126.09%Miss-15500.0%
    Sep 23
    		$-0.13N/AN/ABeat-762.0%
    Jun 23
    		$-0.12N/AN/ABeat-254.1%
    Mar 23
    		$-0.05N/AN/ABeat-160.7%
    Dec 22
    		$-0.01$0.00N/AMiss-111.1%
    Sep 22
    		$0.02$0.00N/ABeat-66.7%
    Jun 22
    		$0.08$0.00N/ABeat+700.0%
    Mar 22
    		$0.09$0.00N/ABeat+1000.0%
    Dec 21
    		$0.09$0.00N/ABeat-
    Sep 21
    		$0.06$0.00N/ABeat-
    Jun 21
    		$0.01$0.00N/ABeat-
    Mar 21
    		$-0.01$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.71EV/EBITDA-5.96x
    Price/FCF-12.39xFCF Yield-8.07%
    Profitability
    Profit Margin-62.60%Operating Margin-86.00%
    ROE-496.20%ROIC-58.89%
    Financial Health
    Debt/Equity5.05xInterest Coverage-4.00x
    Current Ratio5.35xQuick Ratio4.97x
    Trading Statistics
    Beta0.43Avg Volume185.44K
    52-Week High$7.9552-Week Low$2.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.12
    SMA 20$5.21
    SMA 50$4.67
    SMA 200$4.82
    EMA 10$5.05
    EMA 20$5.03
    EMA 50$4.74
    EMA 200$4.65

    MACD

    Line: 0.09Signal: 0.19Hist: -0.10

    ADX

    ADX: 22.5+DI: 18.5-DI: 17.5

    Aroon & PSAR

    Aroon Up52.0
    Aroon DownN/A
    PSAR$5.36

    Bollinger Bands

    Upper Band$5.89
    Lower Band$4.53
    %B Position2627%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    49.6

    Momentum Oscillators

    Stoch %K16.3
    Stoch %D18.7
    Williams %R-79.3
    ROC (10d)-6.1%
    Momentum-0.32
    CCI (20d)-67.0
    MFI (14d)52.9

    Volatility Measures

    ATR (14d)$0.32(6.5%)
    StdDev (20d)0.34
    Hist Vol70.5%(High)

    Volume Flow

    VWAP$4.93
    OBV5.3M
    AD Line5.2M
    CMF (20d)0.151

    Volume Metrics

    Avg Vol (20d)188.0K
    Vol Ratio0.4x(Low)
    VWMA (20d)$5.28

    Pivot Points

    R3$5.69
    R2$5.46
    R1$5.15
    Pivot Point$4.92
    S1$4.61
    S2$4.38
    S3$4.07

    Advanced Oscillators

    TSI9.81
    Ultimate Osc41.4
    KST158.07

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$11.41M$8.90M$13.21M$11.57M$11.21M$9.17M$8.26M$7.35M$7.36M$6.46M$5.72M$5.19M
    Cost of Revenue$1.51M$1.23M$1.76M$1.91M$1.80M$1.50M$1.22M$1.00M$912,000$971,000$582,000$589,000
    Gross Profit$9.90M$7.67M$11.44M$9.66M$9.41M$7.67M$7.04M$6.34M$6.45M$5.49M$5.14M$4.60M
    Operating Expenses$19.71M$16.08M$14.71M$18.67M$16.74M$15.00M$14.63M$15.08M$14.63M$17.16M$19.44M$23.22M
    R&D$3.14M$3.22M$2.57M$5.18M$3.67M$3.02M$2.96M$4.22M$4.67M$5.84M$7.80M$9.51M
    SG&A$5.16M$5.45M$4.17M$6.66M$5.91M$5.25M$4.66M$4.73M$3.96M$4.63M$6.04M$9.03M
    Operating Income$-9,813,000$-8,411,000$-3,271,000$-9,014,000$-7,332,000$-7,329,000$-7,580,000$-8,739,000$-8,174,000$-11,672,000$-14,304,000$-18,616,000
    Interest Income$457,000$164,000$177,000$170,000$134,000$74,000$57,000$158,000$97,000$92,000$244,000$116,000
    Interest Expense$1.49M$1.44M$1.45M$1.46M$1.42M$1.21M$1.07M$1.14M$877,000$3,000$3,000$4,000
    Income Before Tax$-9,183,000$1.54M$-9,753,000$-10,806,000$-8,291,000$-10,370,000$-10,109,000$-2,402,000$-4,325,000$-13,203,000$-35,695,000$-1,425,000
    Income Tax Expense$4,000$4,000$0$5,000$-3,000$5,000$-1,000$-3,000$7,000$3,000$1,000$0
    Net Income$-9,187,000$1.54M$-9,753,000$-10,811,000$-8,288,000$-10,375,000$-10,108,000$-2,399,000$-4,332,000$-13,206,000$-35,696,000$-1,425,000
    EBITDA$-7,678,000$3.25M$-8,070,000$-9,662,000$-6,580,000$-8,828,000$-8,727,000$-1,220,000$-2,933,000$-13,117,000$-35,872,000$-1,251,000
    EBIT$-8,150,000$2.81M$-8,478,000$-9,516,000$-7,002,000$-9,235,000$-9,098,000$-1,418,000$-3,545,000$-13,292,000$-35,936,000$-1,537,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TLSI

    News

    TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference

    TriSalus Life Sciences outlined its commercial expansion, product pipeline, and clinical strategy at Canaccord Genuity’s Global Growth Conference, focusing on its pressure-enabled delivery technology for solid tumors. The company is actively expanding its sales force and increasing physician education to broaden product adoption. A key potential catalyst is the pending FDA clearance for TriNav ADVANCE, which could significantly expand market reach, and management projects strong gross margins and a path to cash-flow positivity with new CMS reimbursement codes.

    MarketBeat•8/18/26•
    Bullish

    TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen

    Wall Street Zen has downgraded TriSalus Life Sciences (NASDAQ:TLSI) from "Hold" to "Sell," while the overall analyst consensus for the stock remains a "Hold" with an average price target of $7.50. Despite the downgrade, TriSalus shares opened at $5.27, following a 6.4% decline, and its recent quarterly results met earnings expectations and exceeded revenue estimates. The company, a clinical-stage biotechnology firm focusing on oncology therapies, has seen varied ratings from other analysts, including reaffirmed "Sell" and "Buy" ratings with adjusted price targets.

    MarketBeat•8/15/26•
    Somewhat-Bearish

    CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7

    CCORF has reiterated its Buy rating for TriSalus Life Sciences (TLSI.US), while also maintaining its target price of $7. This indicates a continued positive outlook from CCORF on the company's stock performance.

    Moomoo•8/13/26•
    Bullish

    TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins

    TriSalus Life Sciences (TLSI) stock surged 15.2% despite the company reporting deeper losses in Q2 2026, with a net loss of US$9.2m and an adjusted EBITDA loss of US$7.1m. While revenue remained flat at US$11.4m, the gross margin improved to 86.8%, indicating strong unit economics for its drug delivery platform. Investors are weighing the high margins and operational milestones against increased commercial spending and delayed regulatory approvals.

    Sahm•8/9/26•
    Neutral

    Securities Fraud Investigation Into TriSalus Life Sciences Inc

    Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into TriSalus Life Sciences Inc. (NASDAQ: TLSI) on behalf of investors who lost money. The investigation follows a significant drop in TriSalus's stock price after the company reported lower-than-expected Q1 revenues and cut its full-year revenue guidance, attributing the shortfall to commercial expansion issues and a five-month delay in FDA clearance for its TriNav Advance product. Shareholders are urged to contact the firm to learn more about potentially recovering their losses.

    The National Law Review•8/8/26•
    Bearish

    Frequently Asked Questions About TLSI

    Does TLSI pay dividends?
    TriSalus Life Sciences Inc. (TLSI) does not currently pay a regular dividend.
    What is TLSI's market cap?
    TriSalus Life Sciences Inc. (TLSI) has a market capitalization of $297.40M with a current stock price of $4.95.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In